Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
May 9, 2022
The Column Group announces the hiring of Dr. Hui Tian. Previously, Dr. Tian was a founding member of NGM Biopharmaceuticals and most recently served as Senior Vice President of Research. In this role, he was responsible for discovery research across multiple therapeutic areas including metabolic diseases, retinal diseases and cancer. In a span of 14 …
Dr. Hui Tian joins The Column Group as Venture Partner Read More »
The Column Group announces the promotion of Dr. Sarah Hymowitz from Venture Partner to Partner. Dr. Hymowitz has been with TCG since 2021.